Business news – Page 102
-
OpinionFluorine fanatics
Some medicinal chemists can't get enough fluorines in their molecules. Derek Lowe explains the love-hate relationship
-
Business
Business roundup: January 2011
New pharma bosses take up challenge Can Ian Read (L) and Ken Frazier (R) solve the big pharma problem? Two of the big US pharma companies have appointed new chief executives. Jeff Kindler has unexpectedly retired from Pfizer after four and a half years as chief ...
-
OpinionWe need more surprises
Who's that asleep at the back? Don't be too quick to blame yourself when tedious talks and soporific seminars fail to inspire, says Derek Lowe
-
Business
Business roundup: December 2010
Polished performance from Pradaxa The US Food and Drug Administration (FDA) has approved Pradaxa (dabigatran), made by Boehringer Ingelheim, for the prevention of stroke and blood clots in patients with abnormal heart rhythm, known as atrial fibrillation. Source: © Paul Gunning / Science Photo Library ...
-
OpinionThe 'blockbuster mentality’
Should companies focus on big markets and the blockbuster dream? The more modern approaches are not without risks, says Derek Lowe
-
Business
Business roundup: November 2010
Sanofi gets hostile Sanofi-Aventis has taken its $69-per-share (£44-per-share) bid to the Genzyme shareholders, signalling its intent to acquire the US biotech with or without the support of its board - which has unanimously rejected the offer and advised shareholders to hold fast. The Sanofi offer, which values Genzyme ...
-
OpinionThe quiet comeback of 'combi-chem'
Derek Lowe investigates the comeback combinatorial chemistry has made in the field of drug discovery
-
Business
Business roundup: October 2010
Sanofi bid too low says Genzyme Source: © SANOFI AVENTIS Christopher Viehbacher: ’offer provides immediate and certain value Sanofi-Aventis is not being bashful about its designs on Genzyme any longer. The French pharma giant has offered $69 (£45) per share in an all-cash bid that values the ...
-
Opinion
How much selectivity do you want?
Derek Lowe considers the quandaries of living in the age of the kinase
-
Business
Business roundup: September 2010
Falling sales at Johnson & Johnson ’s (J&J) consumer healthcare division have hurt the pharma giant’s US sales, which fell 2.8 per cent compared to the same period last year. Globally, sales for the company’s consumer goods division fell 5.4 per cent to $3.6 billion (£2.3 billion) - ...
-
Opinion
Missing methods
Derek Lowe reminisces about lost laboratory techniques and wonders which will be next to go
-
Business
Business roundup: August 2010
Bittersweet victory for GSK’s Avandia GlaxoSmithKline (GSK) has received a muted ’thumbs up’ from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration (FDA) will allow the UK-based pharma giant to continue selling the drug in ...
-
Business
Business roundup: July 2010
Eight convicted for Bhopal disaster More than 25 years after one of the worst industrial accidents in living memory, the Magistrate’s court in Bhopal, India, has convicted eight former Union Carbide employees of ’causing death by criminal negligence’. The eight convicted include Keshub Mahindra, former chairman of the Indian subsidiary ...
-
Opinion
If something can’t go on, then it won’t
Derek Lowe looks into his crystal ball to see what the future of medicinal chemistry might be
-
Business
Business roundup: June 2010
The green shoots of a chemical spring Recent data seem to suggest that the chemical industries have weathered the worst of the economic storm, at least for now. Cefic, the European Chemical Industry Council, has updated its Chemical Trends report which shows that the European chemicals industry has now ...
-
OpinionDeath by assay result
Derek Lowe wonders whether tagging molecules with fluorescent labels for assay is like tracking the members of a shoal of fish by tying each one to a whale
-
Business
Business roundup: May 2010
Comparative effectiveness With the US coming to terms with the biggest changes to its healthcare system in 60 years, a measure hidden deep within the 2400-page law has come to light - that of comparative effectiveness. The measure will create an institute funded by around $500 million (£335 million) a ...
-
Opinion
How to be an organised scientist
Derek Lowe waxes lyrical about the joys of the electronic lab notebook
-
Business
Business roundup: April 2010
Merck joins the cost-cutting crowd Following its $41 billion (£27 billion) merger with Schering-Plough, US drug giant Merck & Co. has announced a ’merger restructuring plan’ that in its first phase will see 17,500 jobs cut. At the time of the merger announcement, the company said it aimed to shave ...